Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (213)	5/10/2001 12:35:12 PM
From: Jim Oravetz	Read Replies (1) of 278

Forest Labs Says Alzheimer's Drug Effective In Studies Dow Jones Newswires NEW YORK -- Forest Laboratories Inc. (FRX) reported that new data from a phase III clinical study demonstrates the novel neuroprotective effects and clinical potential of memantine drug, an investigational new drug being developed as a treatment for Alzheimer's disease. Forest intends to submit an New Drug Application with the Food and Drug Administration for Alzheimer's around the end of 2001. In a press release Thursday, the company said the data demonstrated a possible benefit for moderately severe to severe Alzheimers patients treated with memantine, relative to those treated with placebo, as shown by positive outcomes in measures of cognition, day-to-day function and overall performance. Forest Laboratories develops and makes generic brand over-the-counter prescription drugs.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next